Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Mavacoxib
Price:
Purity: 98.0%
Stocking Period: 10 Day
Contact: Huang

ShangHai DC Chemicals Co.,Ltd
China
Product Name: PHA-739521
Price: ￥Inquiry/1g
Purity: 98.9%
Stocking Period: 1 Day
Contact: Tony Lai

DC Chemicals Limited
China
Product Name: PHA-739521
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: 4-[5-(4-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL]BENZENE-1-SULFONAMIDE
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

170569-88-7

170569-88-7 structure

Name: Mavacoxib
Chemical Name: mavacoxib
CAS Number: 170569-88-7
Molecular Formula: C₁₆H₁₁F₄N₃O₂S
Molecular Weight: 385.336
Catalog: Signaling Pathways Immunology/Inflammation COX
Create Date: 2016-08-19 10:12:42
Modify Date: 2024-01-06 16:53:56
Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs[1].

Name	mavacoxib
Synonyms	4-[5-(4-Fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide Mavacoxib PHA 739,521 Benzenesulfonamide, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-

Description	Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs[1].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> COX
Target	COX-2
In Vitro	Mavacoxib (0-200 μM; 72 hours; CSKOS, U2OS, REM, K9TCC and T24 cells) treatment reduces cell viability in a dose-dependent manner. However, sensitivity to Mavacoxib varied between the cell lines, with IC50 values ranging from 34.5 μM to 157.7 μM. The IC50 values of U2OS, KTOSA5, CSKOS, REM, LILY, K9TCC, K9TCC-AXA, K9TCC-In, K9TCC-Sh, T24, 5637 and HT-1376 cells are 52.6 μM, 89.8 μM, 106.3 μM, 66.6 μM, 97.5 μM, 54.9 μM, 34.5 μM, 78.7 μM, 50.7 μM, 63.4 μM, 72.5 μM and 157.7 μM, respectively[1]. Mavacoxib (0-200 μM; 48 hours; KTOSA5, REM, LILY, K9TCC, U2OS, and T24 cells) treatment can induce caspase-dependent apoptosis in a number of cell lines[1]. Mavacoxib (0-75 μM; 24 hours; CSKOS, U2OS, REM, K9TCC and T24 cells) treatment down-regulates the expression of p-Akt in CSKOS cells in in a dose-dependent manner, as is total Akt in U2OS cells. In REM cells, both p-ERK and p-Akt are increased in expression with increasing doses of Mavacoxib, and in K9TCC cells p-ERK expression is also increased with Mavacoxib treatment[1]. Cell Viability Assay[1] Cell Line: CSKOS, U2OS, REM, K9TCC and T24 cells Concentration: 0 μM, 0.04 μM, 25 μM, 50 μM, 75 μM, 100 μM, 125 μM, 150 μM, 175 μM, 200 μM Incubation Time: 72 hours Result: Cell viability was reduced in a dose-dependent manner. Apoptosis Analysis[1] Cell Line: KTOSA5, REM, LILY, K9TCC, U2OS, and T24 cells Concentration: 0 μM, 50 μM, 100 μM, 200 μM Incubation Time: 48 hours Result: Induced apoptosis in canine and human cancer cell lines. Cell Viability Assay[1] Cell Line: CSKOS, U2OS, REM, K9TCC and T24 cells Concentration: 0 μM, 25 μM, 50 μM or 75 μM Incubation Time: 24 hours Result: In CSKOS cells, p-Akt was downregulated, as was total Akt in U2OS cells. In REM cells, both p-ERK and p-Akt were increased in expression, and in K9TCC cells p-ERK expression was also increased.
In Vivo	Osteoarthritic dogs enrolled in the studies are randomized to receive treatment with Mavacoxib and daily placebo for carprofen or placebo for Mavacoxib and daily carprofen at a nominal dose of 4 mg/kg BW. Mavacoxib is administered in both studies with a 2-week interval between the first and second doses but with monthly dosing thereafter. The nominal Mavacoxib doses in Studies 1 and 2 are 4 and 2 mg/kg BW, respectively. Seven Mavacoxib doses are administered in Study 1, but only five doses in Study 2. In Study 1, Mavacoxib is administered without regard to the timing of meals, but in Study 2, all of the Mavacoxib doses are administered with food[2].
References	[1]. Hurst EA, et al. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels. Vet Comp Oncol. 2019 Jun;17(2):194-207. [2]. Cox SR, et al. Population pharmacokinetics of mavacoxib in osteoarthritic dogs. J Vet Pharmacol Ther. 2011 Feb;34(1):1-11.

Density	1.5±0.1 g/cm3
Boiling Point	519.8±60.0 °C at 760 mmHg
Molecular Formula	C₁₆H₁₁F₄N₃O₂S
Molecular Weight	385.336
Flash Point	268.2±32.9 °C
Exact Mass	385.050812
PSA	86.36000
LogP	3.69
Vapour Pressure	0.0±1.4 mmHg at 25°C
Index of Refraction	1.603
Storage condition	2-8°C